the role of imetelstat in the treatment of myelofibrosis and insights into the impactmf study
Published 1 year ago • 1.8K plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
1:15
ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
-
1:44
an update on imetelstat in r/r myelofibrosis
-
3:35
new phase iii trial of imetelstat versus bat in jak inhibitor-refractory myelofibrosis
-
3:13
therapies for patients who progress on jak inhibitors: imetelstat, navtemadlin, selinexor & tp-3654
-
1:48:47
hematology: hemoglobin and iron metabolism
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
2:25
what is myelofibrosis?
-
1:30
the safety profile of imetelstat in myeloid malignancies
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:04
exciting updates in mf: novel targets and agents
-
2:57
imetelstat for lr-mds: insights from the imerge trial
-
1:24
imetelstat in high-risk triple-negative myelofibrosis
-
2:51
analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
-
1:39
the mechanism of action of navtemadlin and its role in mf
-
2:12
navtemadlin and its role in the treatment of r/r myelofibrosis
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
2:01
early myelofibrosis: current treatment approaches and novel strategies
-
1:14
promising novel agents in aml: menin inhibitors
-
0:35
novel therapeutics in essential thrombocythemia